Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05054725 |
Recruitment Status :
Active, not recruiting
First Posted : September 23, 2021
Last Update Posted : April 3, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Non-Small Cell Lung Cancer | Drug: RMC-4630 Drug: Sotorasib | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 47 participants |
Allocation: | Non-Randomized |
Intervention Model: | Sequential Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 2, Open-Label, Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies |
Actual Study Start Date : | December 30, 2021 |
Estimated Primary Completion Date : | September 30, 2023 |
Estimated Study Completion Date : | March 3, 2024 |
Arm | Intervention/treatment |
---|---|
Experimental: RMC-4630 and sotorasib, Safety Run-in
Safety Run-In: RMC-4630 and sotorasib |
Drug: RMC-4630
RMC-4630 administered orally as a capsule
Other Name: SAR442720 Drug: Sotorasib Sotorasib administered orally as a tablet
Other Names:
|
Experimental: RMC-4630 and sotorasib, Expansion
Dose Expansion: RMC-4630 and sotorasib |
Drug: RMC-4630
RMC-4630 administered orally as a capsule
Other Name: SAR442720 Drug: Sotorasib Sotorasib administered orally as a tablet
Other Names:
|
- Objective response rate (ORR) [ Time Frame: approximately 12 months ]ORR as assessed per RECIST v1.1
- Adverse Events [ Time Frame: approximately 12 months ]Number of Participants with Adverse Events
- Serious Adverse Events [ Time Frame: approximately 12 months ]Number of Participants with Serious Adverse Events
- Vital signs [ Time Frame: approximately 12 months ]Number of subjects with clinically significant changes in vital signs
- Clinical laboratory test values [ Time Frame: approximately 12 months ]Number of subjects with clinically significant changes in clinical laboratory test values
- ECGs Measurements [ Time Frame: approximately 12 months ]Number of subjects with clinically significant changes in ECGs Measurements
- Concentration of RMC-4630 [ Time Frame: approximately 12 months ]Trough Concentration of RMC-4630
- Concentration of sotorasib [ Time Frame: approximately 12 months ]Trough Concentration of sotorasib
- Duration of response (DOR) [ Time Frame: approximately 12 months ]DOR as assessed by RECIST v1.1
- Disease Control Rate (DCR) [ Time Frame: approximately 12 months ]DCR as assessed by RECIST v1.1
- Progression-free survival (PFS) [ Time Frame: approximately 12 months ]PFS as assessed by RECIST v1.1
- Overall survival (OS) [ Time Frame: approximately 12 months ]Overall survival (OS)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Subject must be ≥18 years of age.
- Subject must have pathologically documented, locally advanced or metastatic KRASG12C NSCLC (not amenable to curative surgery) that has progressed on prior standard therapies (no more than 3 prior lines of therapies are allowed)
Exclusion Criteria
- Primary central nervous system (CNS) tumors
- Known or suspected leptomeningeal or brain metastases or spinal cord compression
- Clinically significant cardiac disease
- Known impairment of GI function that would alter the absorption
- Active autoimmune disease requiring systemic treatment within past 2 years
- History of severe allergic reactions to any of the study intervention components
- Major surgical procedures within 28 days or non-study-related minor procedures within 7 days of treatment.
- Prior therapy with KRASG12C inhibitor and/or SHP2 inhibitor
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05054725
Study Director: | Revolution Medicines, Inc. | Revolution Medicines, Inc. |
Responsible Party: | Revolution Medicines, Inc. |
ClinicalTrials.gov Identifier: | NCT05054725 |
Other Study ID Numbers: |
RMC-4630-03 |
First Posted: | September 23, 2021 Key Record Dates |
Last Update Posted: | April 3, 2023 |
Last Verified: | October 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
SHP2 NSCLC KRAS G12C BRAF Class 1/2/unclassified KRAS amplification KRAS mutation STK11/LKB1 KEAP1 PIK3CA ATRX |
BRCA2 carcinoma, non-small lung cancer bronchial neoplasms lung neoplasms respiratory tract neoplasms neoplasms by site neoplasms lung diseases respiratory tract diseases |
Lung Neoplasms Carcinoma, Non-Small-Cell Lung Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases |
Carcinoma, Bronchogenic Bronchial Neoplasms Sotorasib Immune Checkpoint Inhibitors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents, Immunological Antineoplastic Agents |